Ab68 works by inhibiting the release of CD38, an enzyme found elevated in patients with scleroderma. CD38 causes a metabolic change, breaking down and reducing the levels of NAD+, a coenzyme necessary ...
US biotech major Biogen revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, has received ...
On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...
Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves ...
The new first-line indication joins two previous approvals of the CD38 antibody for later-line indications, one for relapsed disease with carfilzomib and dexamethasone and the other with ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not eligible ...
Since 2018, the J&J med has been the lone CD38 antibody approved for first-line myeloma. For that Darzalex approval, the FDA cleared the med to be paired with bortezomib, melphalan and prednisone ...
Sarclisa is the first anti-CD38 therapy in combination with SoC VRd to reduce disease progression or death by 40% vs. VRd alone. At a median follow-up of 59.7 months, the median PFS with the ...
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
The following is a summary of “Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback